Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 3/2015

01.09.2015 | Post-Prostatectomy and Acquired Voiding Dysfunction (V Tse, Section Editor)

Pelvic Irradiation and Its Effects on the Lower Urinary Tract: a Literature Review

verfasst von: Cristiano Mendes Gomes, Ricardo Vita Nunes, Vincent Tse

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

The benefit of radiotherapy (RT) for pelvic tumors such as prostate and bladder cancer is well described. As cancer control rates improve, long-term survivorship issues become highly relevant to cancer management and it is essential to better understand the long-term effects of radiation. The risk and nature of radiation toxicity in a patient depend on treatment-related factors such as the total radiation dose, the dose per fraction, and schedule of treatment as well as patient-related factors like age, baseline lower urinary tract symptoms, previous surgery in an irradiated site, and co-morbidities. Radiation may also have a negative impact on the outcomes of surgical procedures for the treatment of lower urinary tract symptoms. Technical developments in radiation therapy such as intensity-modulated radiotherapy and the use of various forms of image-guided radiotherapy have enabled a decrease in the dose in organs surrounding the tumor that in many situations has reduced severe radiation-induced toxicities.
Literatur
1.
2.
3.
Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31(5):1257–80.CrossRefPubMed
4.
Elliott SP, Meng MV, Elkin EP, McAninch JW, Duchane J, Carroll PR. Incidence of urethral stricture after primary treatment for prostate cancer: data from CaPSURE. J Urol. 2007;178(2):529–34.CrossRefPubMed
5.
6.
Levenback C, Gershenson DM, McGehee R, Eifel PJ, Morris M, Burke TW. Enterovesical fistula following radiotherapy for gynecologic cancer. Gynecol Oncol. 1994;52(3):296–300.CrossRefPubMed
7.
Cohen KH, Teh BS, Paulino AC, Butler EB. Ureteral stenosis after postprostatectomy intensity-modulated radiotherapy. Am J Clin Oncol. 2010;33(1):108.CrossRefPubMed
8.
Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003;4(9):529–36.CrossRefPubMed
9.
Trott KR, Doerr W, Facoetti A, Hopewell J, Langendijk J, van Luijk P, et al. Biological mechanisms of normal tissue damage: importance for the design of NTCP models. Radiother Oncol. 2012;105(1):79–85.CrossRefPubMed
10.
Sanfilippo NJ, Cooper BT. Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations. Am J Clin Exp Urol. 2014;2(4):286–93.PubMedCentralPubMed
11.•
Zaorsky NG, Harrison AS, Trabulsi EJ, Gomella LG, Showalter TN, Hurwitz MD, et al. Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol. 2013;10(10):565–79. This is a nice review of the evolution of radiotherapy techniques applied to prostate cancer.CrossRefPubMed
12.
Thames Jr HD, Withers HR, Peters LJ, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys. 1982;8(2):219–26.CrossRefPubMed
13.
Yoon H, Cha J, Keum K, Lee H, Nam E, Kim S, et al. Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis. Radiat Oncol. 2015;10(1):18.PubMedCentralCrossRefPubMed
14.
Hopewell JW, Trott KR. Volume effects in radiobiology as applied to radiotherapy. Radiother Oncol. 2000;56(3):283–8.CrossRefPubMed
15.
Paulino AC, Constine LS, Rubin P, Williams JP. Normal tissue development, homeostasis, senescence, and the sensitivity to radiation injury across the age spectrum. Semin Radiat Oncol. 2010;20(1):12–20.CrossRefPubMed
16.••
Jarosek SL, Virnig BA, Chu H, Elliott SP. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both. Eur Urol. 2015;67(2):273–80. This study shows increased risk of urinay adverse events with combination of treatment modalities and with time since treatment.CrossRefPubMed
17.
Chon BH, Loeffler JS. The effect of nonmalignant systemic disease on tolerance to radiation therapy. Oncologist. 2002;7(2):136–43.CrossRefPubMed
18.
19.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.CrossRefPubMed
20.
Bolla M, van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–73.CrossRefPubMed
21.
D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289–95.PubMed
22.
Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015;33(4):332–9.CrossRefPubMed
23.
24.
Bolla M, Van PH, Tombal B, Vekemans K, Da PL, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–27.CrossRefPubMed
25.
Bolla M, Van PH, Collette L, Van CP, Vekemans K, Da PL, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572–8.CrossRefPubMed
26.
Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014;65(6):1034–43.CrossRefPubMed
27.
Ataman F, Zurlo A, Artignan X, van Tienhoven G, Blank LE, Warde P, et al. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer. 2004;40(11):1674–81.CrossRefPubMed
28.
Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17(2):517–22.PubMed
29.
Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999;85(11):2460–8.CrossRefPubMed
30.
Zietman AL, DeSilvio ML, Slater JD, Rossi Jr CJ, Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294(10):1233–9.CrossRefPubMed
31.
Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol. 2002;167(1):123–6.CrossRefPubMed
32.
Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61(4):1019–34.CrossRefPubMed
33.
Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990–6.CrossRefPubMed
34.
Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85–31, 86–10, and 92–02. Int J Radiat Oncol Biol Phys. 2008;70(2):437–41.PubMedCentralCrossRefPubMed
35.
Chong KT, Hampson NB, Corman JM. Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis. Urology. 2005;65(4):649–53.CrossRefPubMed
36.
Fransson P. Patient-reported lower urinary tract symptoms, urinary incontinence, and quality of life after external beam radiotherapy for localized prostate cancer—15 years’ follow-up. A comparison with age-matched controls. Acta Oncol. 2008;47(5):852–61.CrossRefPubMed
37.
Hathout L, Folkert MR, Kollmeier MA, Yamada Y, Cohen GN, Zelefsky MJ. Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning. Int J Radiat Oncol Biol Phys. 2014;90(2):312–9.CrossRefPubMed
38.
Zelefsky MJ, Yamada Y, Cohen GN, Shippy A, Chan H, Fridman D, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67(1):65–70.CrossRefPubMed
39.
Chen AB, D’Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006;24(33):5298–304.CrossRefPubMed
40.
Anderson JF, Swanson DA, Levy LB, Kuban DA, Lee AK, Kudchadker R, et al. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology. 2009;74(3):601–5.CrossRefPubMed
41.
Sarosdy MF. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer. 2004;101(4):754–60.CrossRefPubMed
42.
Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011;79(5):1310–7.CrossRefPubMed
43.
Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2009;74(5):1405–18.CrossRefPubMed
44.
Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American College of Radiology 95–09. J Clin Oncol. 2010;28(7):1106–11.PubMedCentralCrossRefPubMed
45.
Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365(2):107–18.CrossRefPubMed
46.
Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74.CrossRefPubMed
47.
Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61(4):1019–34.CrossRefPubMed
48.
Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176(4 Pt 1):1415–9.CrossRefPubMed
49.
Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012;13(1):43–54.CrossRefPubMed
50.
Dearnaley DP. Hypofractionated radiotherapy in prostate cancer. Lancet Oncol. 2015;16(3):237–8.CrossRefPubMed
51.
52.
Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007;69(2):444–53.PubMedCentralCrossRefPubMed
53.
Vargas C, Fryer A, Mahajan C, Indelicato D, Horne D, Chellini A, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(3):744–51.CrossRefPubMed
54.
Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Sturmer T, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307(15):1611–20.PubMedCentralCrossRefPubMed
55.•
Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013;119(9):1729–35. This study compares radiation toxicity patterns of different radiation modalities.CrossRefPubMed
56.
Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013;105(1):25–32.PubMedCentralCrossRefPubMed
57.
Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach III M, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol. 2012;61(3):443–51.CrossRefPubMed
58.
Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27(18):2924–30.CrossRefPubMed
59.
Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol. 2009;181(3):956–62.PubMedCentralCrossRefPubMed
60.
Taylor KL, Luta G, Miller AB, Church TR, Kelly SP, Muenz LR, et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2012;30(22):2768–75.PubMedCentralCrossRefPubMed
61.
Aboseif SR, O’Connell HE, Usui A, McGuire EJ. Collagen injection for intrinsic sphincteric deficiency in men [see comments]. J Urol. 1996;155(1):10–3.CrossRefPubMed
62.
Martins FE, Bennett CJ, Dunn M, Filho D, Keller T, Lieskovsky G. Adverse prognostic features of collagen injection therapy for urinary incontinence following radical retropubic prostatectomy [see comments]. J Urol. 1997;158(5):1745–9.CrossRefPubMed
63.
Lee SW, Kang JH, Sung HH, Jeong US, Lee YS, Baek M, et al. Treatment outcomes of transurethral macroplastique injection for postprostatectomy incontinence. Korean J Urol. 2014;55(3):182–9.PubMedCentralCrossRefPubMed
64.
Westney OL, Bevan-Thomas R, Palmer JL, Cespedes RD, McGuire EJ. Transurethral collagen injections for male intrinsic sphincter deficiency: the University of Texas-Houston experience. J Urol. 2005;174(3):994–7.CrossRefPubMed
65.
Torrey R, Rajeshuni N, Ruel N, Muldrew S, Chan K. Radiation history affects continence outcomes after advance transobturator sling placement in patients with post-prostatectomy incontinence. Urology. 2013;82(3):713–7.CrossRefPubMed
66.
Cornu JN, Sebe P, Ciofu C, Peyrat L, Cussenot O, Haab F. Mid-term evaluation of the transobturator male sling for post-prostatectomy incontinence: focus on prognostic factors. BJU Int. 2011;108(2):236–40.CrossRefPubMed
67.
Giberti C, Gallo F, Schenone M, Cortese P, Ninotta G. The bone anchor suburethral synthetic sling for iatrogenic male incontinence: critical evaluation at a mean 3-year follow up. J Urol. 2009;181(5):2204–8.CrossRefPubMed
68.•
Bates AS, Martin RM, Terry TR. Complications following artificial urinary sphincter placement after radical prostatectomy and radiotherapy: a meta-analysis. BJU Int 2015. doi:10.​1111/​bju.​13048. This is a nice review of the complications of artificial urinary sphincter placement in patients who received radiotherapy for prostate cancer.
69.
Hofer MD, Zhao LC, Morey AF, Scott JF, Chang AJ, Brandes SB, et al. Outcomes after urethroplasty for radiotherapy induced bulbomembranous urethral stricture disease. J Urol. 2014;191(5):1307–12.CrossRefPubMed
70.
Ahyai SA, Schmid M, Kuhl M, Kluth LA, Soave A, Riechardt S, et al. Outcomes of ventral-onlay buccal mucosa graft urethroplasty in patients after radiotherapy. J Urol 2015. doi:10.​1016/​j.​juro.​2015.​03.​116.
71.
Meeks JJ, Brandes SB, Morey AF, Thom M, Mehdiratta N, Valadez C, et al. Urethroplasty for radiotherapy induced bulbomembranous strictures: a multi-institutional experience. J Urol. 2011;185(5):1761–5.CrossRefPubMed
72.
Boone TB. Transurethral resection versus intermittent catheterization in patients with retention after combined brachytherapy/external beam radiotherapy for prostate cancer: intermittent catheterization. J Urol. 2013;189(3):801–2.CrossRefPubMed
73.
Kollmeier MA, Stock RG, Cesaretti J, Stone NN. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol. 2005;173(3):808–12.CrossRefPubMed
74.
Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, et al. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):204–12.CrossRefPubMed
75.
Palmer DA, Buckley JC, Zinman LN, Vanni AJ. Urethroplasty for high risk, long segment urethral strictures with ventral buccal mucosa graft and gracilis muscle flap. J Urol. 2015;193(3):902–5.CrossRefPubMed
76.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.CrossRefPubMed
77.
78.
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75.PubMed
79.
Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006;24(3):296–304.CrossRefPubMed
80.
Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001;165(4):1111–6.CrossRefPubMed
81.
Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol. 1999;161(5):1494–7.CrossRefPubMed
82.
Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol. 2008;180(1):121–7.CrossRefPubMed
83.
Hussain SA, Stocken DD, Peake DR, Glaholm JG, Zarkar A, Wallace DM, et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer. 2004;90(11):2106–11.PubMedCentralPubMed
84.
Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89–03, 95–06, 97–06, 99–06. J Clin Oncol. 2009;27(25):4055–61.PubMedCentralCrossRefPubMed
85.
Fokdal L, Hoyer M, Meldgaard P, von der Maase H. Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. Radiother Oncol. 2004;72(2):139–45.CrossRefPubMed
86.
Henningsohn L, Wijkstrom H, Dickman PW, Bergmark K, Steineck G. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol. 2002;62(2):215–25.CrossRefPubMed
87.
Majewski W, Tarnawski R. Acute and late toxicity in radical radiotherapy for bladder cancer. Clin Oncol (R Coll Radiol). 2009;21(8):598–609.CrossRef
88.
Hoskin PJ, Rojas AM, Phillips H, Saunders MI. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. Cancer. 2005;103(11):2287–97.CrossRefPubMed
89.
Turgeon GA, Souhami L, Cury FL, Faria SL, Duclos M, Sturgeon J, et al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2014;88(2):326–31.CrossRefPubMed
90.
Pham D, Roxby P, Kron T, Rolfo A, Foroudi F. Introduction of online adaptive radiotherapy for bladder cancer through a multicentre clinical trial (Trans-Tasman Radiation Oncology Group 10.01): lessons learned. J Med Phys. 2013;38(2):59–66.PubMedCentralCrossRefPubMed
91.
Foroudi F, Wong J, Kron T, Rolfo A, Haworth A, Roxby P, et al. Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study. Int J Radiat Oncol Biol Phys. 2011;81(3):765–71.CrossRefPubMed
92.
McDonald F, Lalondrelle S, Taylor H, Warren-Oseni K, Khoo V, McNair HA, et al. Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation. Clin Oncol (R Coll Radiol). 2013;25(9):549–56.CrossRef
93.
Murthy V, Master Z, Adurkar P, Mallick I, Mahantshetty U, Bakshi G, et al. ‘Plan of the day’ adaptive radiotherapy for bladder cancer using helical tomotherapy. Radiother Oncol. 2011;99(1):55–60.CrossRefPubMed
94.
Pos F, Remeijer P. Adaptive management of bladder cancer radiotherapy. Semin Radiat Oncol. 2010;20(2):116–20.CrossRefPubMed
Metadaten
Titel
Pelvic Irradiation and Its Effects on the Lower Urinary Tract: a Literature Review
verfasst von
Cristiano Mendes Gomes
Ricardo Vita Nunes
Vincent Tse
Publikationsdatum
01.09.2015
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 3/2015
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-015-0316-5

Weitere Artikel der Ausgabe 3/2015

Current Bladder Dysfunction Reports 3/2015 Zur Ausgabe

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Emphysematous Pyelonephritis: a Review of a Rare Condition

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Urinary Tract Infections in the Elderly

Erratum

Erratum to: Neurogenic Bladder Secondary to Congenital Spinal Lesions

Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

Posterior Urethral Valves

Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

Neurogenic Bladder Secondary to Congenital Spinal Lesions

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Update in Diagnosis and Treatment of Chronic Pelvic Pain Syndromes

Neu im Fachgebiet Urologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise